It has been found that due to the increase in the amount of beta-catenin, cyclin D1 and c-myc activation generates which leads to the resistance to lenidomide in multiple myeloma (Bjorklund et al., 2011[1]). Here, CCND1 is linked to plasma cell myeloma.